Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.83 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28882568 | 0.98 | BCHE (0.80) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL11475158 | 0.91 | BCHE (1.00) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL6759921 | 0.89 | BCHE (0.71) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL6759851 | 0.89 | BCHE (0.71) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL14304932 | 0.87 | BCHE (0.86) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL6756956 | 0.86 | BCHE (0.67) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL6141660 | 0.86 | BCHE (0.83) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL14303261 | 0.86 | BCHE (0.83) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL14303260 | 0.86 | BCHE (0.83) | BCHEEPHX2ARNPC1RAB9A | |
| SCHEMBL14304381 | 0.86 | BCHE (0.83) | BCHEEPHX2ARNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5352677-A | Antihyperlipidemic agents | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0407200-B1 | Cinnamamide derivatives | KANEGAFUCHI CHEMICAL IND (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5294624-A | Antiartheriosclerosis | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5294643-A | Cinnamamide derivative | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0407200-A1 | Cinnamamide derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-01-09 | — | — | EP | disclosed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | disclosed |
| EP-0218753-A1 | Image-recieving element for the silver salt diffusion transfer reversal process | AGFA-GEVAERT N.V. (BE) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | BCHE 2324/4885EPHX2 2387/4885AR 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.